Giovanni A. Salamano M.D. ⚕️🎓
LightNews LightNews
banner
gsalamano.bsky.social
Giovanni A. Salamano M.D. ⚕️🎓
@gsalamano.bsky.social
74 followers 21 following 9 posts
At 65 y.o. Medical Doctor in Italy 👨🏼‍⚕️⚕️💭📒 (📚)
Posts Replies Media Videos
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
New in the January 8, 2026, issue of NEJM:

Evolocumab in Patients without Previous MI or Stroke (VESALIUS-CV trial) nej.md/4oWrIN6

Fish Oil, Cardiovascular Events, and Hemodialysis (PISCES trial) nej.md/49zWuqo

#MedSky
Images and descriptions of what's new on NEJM.org this week
January 8, 2026 at 2:03 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Brain-Penetrant Enzyme Therapy for MPS II nej.md/3Y5bAxp

Talquetamab and Teclistamab for Extramedullary Myeloma (RedirecTT-1 phase 2 study) nej.md/4pKghIv

Subscribe to NEJM for the latest medical research: nej.md/subscribe
January 1, 2026 at 2:34 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
New in the January 1, 2026, issue of NEJM:

Sacituzumab Tirumotecan in EGFR-TKI–Resistant NSCLC (OptiTROP-Lung04 phase 3 trial) nej.md/493hVjl

Osimertinib plus Chemotherapy in 𝘌𝘎𝘍𝘙-Mutated NSCLC (FLAURA2 phase 3 trial) nej.md/4opdBzC
Images and descriptions of what's new on NEJM.org this week
January 1, 2026 at 2:34 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Take a look back at the numbers that went into a year of publishing at the world’s leading medical journal.

To discover the 15 articles NEJM editors selected as among the most impactful in advancing clinical practice and patient care this year, download the Notable Articles of 2025: nej.md/3YD0EXU
December 19, 2025 at 4:19 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
An 𝐚𝐫𝐚𝐜𝐡𝐢𝐝𝐨𝐧𝐢𝐜 𝐚𝐜𝐢𝐝 𝐩𝐚𝐭𝐡𝐰𝐚𝐲 is a pathway that involves the metabolism of arachidonic acid, a polyunsaturated fatty acid released from cell membranes by phospholipases on cellular activation. Full definition of this NEJM Illustrated Glossary term: nej.md/4jfUhna

#MedSky
A visual representation of "arachidonic acid pathway"
December 28, 2025 at 2:07 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Noninferiority of One HPV Vaccine Dose to Two Doses (ESCUDDO trial) nej.md/49OEzg1

High-Dose Rifampin in Tuberculous Meningitis (HARVEST phase 3 trial) nej.md/49iiDsQ

Subscribe to NEJM for the latest medical research: nej.md/subscribe
December 18, 2025 at 2:01 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
New in the December 18/25, issue of NEJM:

ctDNA-Guided Atezolizumab in Bladder Cancer (IMvigor011 phase 3 trial) nej.md/3WIRtEg

Cardiovascular Outcomes with Tirzepatide (SURPASS-CVOT trial) nej.md/4qd5rLx

#MedSky
Images and descriptions of what's new on NEJM.org this week
December 18, 2025 at 2:01 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Ticagrelor and Aspirin after Coronary Surgery (TACSI trial) nej.md/45OjEWN

Disitamab Vedotin plus Toripalimab in Urothelial Cancer (RC48-C016 phase 3 trial) nej.md/3W76VtS

Subscribe to NEJM for the latest medical research: nej.md/subscribe
December 11, 2025 at 2:02 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
New in the December 11, 2025, issue of NEJM:

High-Dose Influenza Vaccine in Older Adults (DANFLU-2 trial) nej.md/4lPGMtT

High-Dose Influenza Vaccine and Hospitalizations (GALFLU trial) nej.md/46712T2
Images and descriptions of what's new on NEJM.org this week
December 11, 2025 at 2:02 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
A new review summarizes the diagnosis and treatment of complex regional pain syndrome, a rare limb-pain disorder. Early rehabilitation and multidisciplinary care are key; most patients improve within 18 months. Read the Clinical Practice article: nej.md/3MSMW0n

@liverpooluni.bsky.social #MedSky
Clinical Practice Complex Regional Pain Syndrome An illustration of the symptoms and signs of complex regional pain syndrome in the affected limb. The NEJM identity sits at the bottom.
December 10, 2025 at 10:40 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
In a Review Article from earlier this year, the authors consider available information about the benefits and risks of testosterone treatment in middle-aged and older men with moderate degrees of hypogonadism. Read the full review: nej.md/4ooeFo7

#MedSky #EndoSky #Urology
December 8, 2025 at 8:20 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Pegcetacoplan in C3 Glomerulopathy and IC-MPGN (VALIANT phase 3 trial) nej.md/4pmT67G

Subscribe to NEJM for the latest medical research: nej.md/subscribe
December 4, 2025 at 2:01 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
New in the December 4, 2025, issue of NEJM:

Glucocorticoids for Community-Acquired Pneumonia (SONIA trial) nej.md/47glh02

Shunting for Idiopathic Normal-Pressure Hydrocephalus (PENS trial) nej.md/41OfPQ5

#MedSky
Images and descriptions of what's new on NEJM.org this week
December 4, 2025 at 2:01 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Daily Mosnodenvir as Dengue Prophylaxis nej.md/48eUJwJ

CRISPR-Cas9 Targeting ANGPTL3 nej.md/43doGvu

Engasertib in Hereditary Hemorrhagic Telangiectasia nej.md/4pz9RMC

Subscribe to NEJM for the latest medical research: nej.md/subscribe
November 27, 2025 at 2:29 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
New in the November 27, 2025, issue of NEJM:

Early Discontinuation of Aspirin after PCI (TARGET-FIRST trial) nej.md/3UKJxS7

Early Withdrawal of Aspirin after PCI (NEO-MINDSET trial) nej.md/3VeTJT8

#MedSky
Images and descriptions of what's new on NEJM.org this week
November 27, 2025 at 2:29 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Joshua A. Boyce, MD, describes two studies implicating intestinally generated cysteinyl leukotrienes in food anaphylaxis. Learn more: nej.md/4rp7MEL

#MedSky #PedSky #Immunology
An illustrated diagram of intestinal mucosal mast cells, cysteinyl leukotrienes, and food-induced (oral) anaphylaxis.
November 22, 2025 at 2:02 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Efficacy and Safety of mRNA Influenza Vaccine (phase 3 trial) nej.md/43udoTG

Belzutifan for Pheochromocytoma or Paraganglioma (LITESPARK-015 phase 2 trial) nej.md/475bfP9

Subscribe to NEJM for the latest medical research: nej.md/subscribe
November 20, 2025 at 2:06 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
New in the November 20, 2025, issue of NEJM:

Potassium for High Risk of Ventricular Arrhythmias (POTCAST trial) nej.md/4oQtHTN

Reducing Antihypertensive Drugs in Nursing Home Residents (RETREAT-FRAIL trial) nej.md/45NUK9v

#MedSky
Images and descriptions of what's new on NEJM.org this week
November 20, 2025 at 2:06 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
𝗠𝗮𝗶𝗻 𝗖𝗮𝗿𝗱𝗶𝗮𝗰 𝗙𝗲𝗮𝘁𝘂𝗿𝗲𝘀 𝗼𝗳 𝗔𝗰𝗿𝗼𝗺𝗲𝗴𝗮𝗹𝘆.

Panel A shows the main cardiac features of acromegaly. The exclamation point (middle image) indicates aortic insufficiency. Panel B shows cardiac ultrasound findings in a representative patient with acromegaly.

Learn more: nej.md/3JPVdBg
Panel A: The main cardiac features of acromegaly. Panel B: Cardiac ultrasound findings in a representative patient with acromegaly.
November 16, 2025 at 2:01 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
A new review updates the pathophysiology and disease course of acromegaly, focusing on the general clinician’s key role in early diagnosis and management.

Read the Review Article “Acromegaly” by Andrea Giustina, MD, and Annamaria Colao, MD, PhD: nej.md/3JPVdBg

#MedSky
Review Article Acromegaly Andrea Giustina, M.D., and Annamaria Colao, M.D., Ph.D. Panel A: An artist’s rendering of the facial features of acromegaly. Panel B: Radiographic orofacial findings in a representative patient with acromegaly.
November 12, 2025 at 11:00 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
New in the November 13, 2025, issue of NEJM:

Deferring Arterial Catheterization in Shock (EVERDAC trial) nej.md/3LmOO0D 

Beta-Blockers after MI without Reduced EF (REBOOT trial) nej.md/45QYbws

#MedSky
Images and descriptions of what's new on NEJM.org this week
November 13, 2025 at 2:02 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Orforglipron, a GLP-1 Receptor Agonist for Obesity (ATTAIN-1 phase 3 trial) nej.md/4n1nSl2

Safety and Immunogenicity of Lassa Fever Vaccine nej.md/47pstZ9

Sevabertinib in HER2-Mutant NSCLC (SOHO-01 phase 1–2 study) nej.md/476jryK

Subscribe to NEJM: nej.md/subscribe
November 6, 2025 at 2:03 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
New in the November 6, 2025, issue of NEJM:

Survival after Chest-Wall Irradiation in Breast Cancer (SUPREMO phase 3 trial) nej.md/3Jxd3sI

Oral Icotrokinra for Plaque Psoriasis (ICONIC-LEAD phase 3 trial) nej.md/3WDM6qg

#MedSky
Images and descriptions of what's new on NEJM.org this week
November 6, 2025 at 2:03 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Three must-read Original Articles that made major news in October:

1️⃣ Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD (PRIMAvera study) nej.md/3KP9Jta

𝗡𝗼𝘁𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗱𝗹𝗶𝗻𝗲:
Vision Restored Using Prosthetic Retinal Implant (The New York Times) nej.md/4hDRGCH

#MedSky
Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD | NEJM
Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...
nej.md
October 31, 2025 at 3:08 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
2️⃣ DB-OTO Gene Therapy for Inherited Deafness (CHORD Study) nej.md/4o7ky8f

𝗡𝗼𝘁𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗱𝗹𝗶𝗻𝗲:
3-year-old born deaf can hear 2 years after breakthrough gene therapy treatment (ABC News) nej.md/43zi3ni
DB-OTO Gene Therapy for Inherited Deafness | NEJM
Genetic deficiency of otoferlin, a protein critical to synaptic transmission by the sensory hair cells of the ear, causes congenital deafness. Medicines to treat the condition are lacking; children...
nej.md
October 31, 2025 at 3:08 PM